{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["209(3)"],"submitter":["Hussain M"],"pubmed_abstract":["<h4>Purpose</h4>This post hoc analysis of PROSPER evaluated the relationship between depth of PSA decline and clinical outcomes in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer.<h4>Materials and methods</h4>PROSPER was an international, randomized, double-blind, placebo-controlled, phase 3 trial that demonstrated significantly improved metastasis-free survival and overall survival with androgen deprivation therapy plus enzalutamide vs placebo. A total of 905 enzalutamide-treated men were included in this post hoc analysis. Metastasis-free survival (primary endpoint) and overall survival (secondary endpoint) were evaluated for 4 mutually exclusive subgroups defined by PSA decline: <50% (reference); ≥50% to <90%; ≥90%, nadir ≥0.2 ng/mL; and ≥90%, nadir <0.2"],"journal":["The Journal of urology"],"pagination":["532-539"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12721655"],"repository":["biostudies-literature"],"pubmed_title":["Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial."],"pmcid":["PMC12721655"],"pubmed_authors":["Shore ND","Saad F","De Giorgi U","Shen Q","Efstathiou E","Lin X","Noerby B","Fizazi K","Hussain M","Sternberg CN","Steinberg J","Sugg J"],"additional_accession":[]},"is_claimable":false,"name":"Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.","description":"<h4>Purpose</h4>This post hoc analysis of PROSPER evaluated the relationship between depth of PSA decline and clinical outcomes in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer.<h4>Materials and methods</h4>PROSPER was an international, randomized, double-blind, placebo-controlled, phase 3 trial that demonstrated significantly improved metastasis-free survival and overall survival with androgen deprivation therapy plus enzalutamide vs placebo. A total of 905 enzalutamide-treated men were included in this post hoc analysis. Metastasis-free survival (primary endpoint) and overall survival (secondary endpoint) were evaluated for 4 mutually exclusive subgroups defined by PSA decline: <50% (reference); ≥50% to <90%; ≥90%, nadir ≥0.2 ng/mL; and ≥90%, nadir <0.2","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-07-15T14:35:44.205Z","creation":"2026-07-06T03:08:13.373Z"},"accession":"S-EPMC12721655","cross_references":{"pubmed":["36756959"],"doi":["10.1097/JU.0000000000003084"]}}